Hetero Labs submits ANDA220421 for Vemagal with standard review priority
Hetero Labs Limited has submitted ANDA220421 for Vemagal, currently under standard review.
Asset / Drug
Drug and asset intelligence for Vemagal with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.